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Original article
Accelerated arterial stiffness occurs in those with diabe-
tes.1 Arterial stiffness may be a result of or a cause of dia-
betic vascular complications such as diabetic nephropathy 
and retinopathy.2 Pulse wave velocity (PWV) is a nonin-
vasive measure of arterial stiffness that predicts mortality 
and cardiovascular events, and also among individuals with 
diabetes.3–5 Given the differences in the predominant com-
ponents of the arterial wall between central and peripheral 
arteries, and the small vessel involvement among those with 
diabetes, we would expect the effect of diabetes on arterial 
stiffness to differ across arterial territories. Carotid-femoral 
PWV (cfPWV) is often considered the reference stand-
ard measurement for central (aortic) stiffness.6,7 Although 
not used clinically in the United States, a recent European 
expert consensus statement suggests that cfPWV >10 m/s 
(1,000 cm/s) be considered among cardiovascular risk fac-
tors and other measures such as electrocardiography, carotid 
intimal media thickness, and albuminuria in classifying car-
diovascular risk for middle-aged adults with hypertension.8 
Higher cfPWV thresholds have been suggested as a reference 
for those aged 70+ years.9 At present, there are no guideline 
recommendations for measurement of PWV among those 
with diabetes.10
As a precursor state to diabetes, prediabetes is associ-
ated with higher burden of prevalent cardiac disease in the 
elderly.11 In a Chinese middle-aged population (N = 4,938), 
an increasingly significant difference in brachial-ankle PWV 
(baPWV) was seen as glucose tolerance worsened from 
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BACKGROUND
To determine whether prediabetes and diabetes in older adults are 
associated with arterial stiffness measured in central and peripheral 
arteries and to examine characteristics that modify these associations.
METHODS
Cohort members attending the 5th exam (2011–2013) of the 
Atherosclerosis Risk in Communities (ARIC) study had pulse wave veloc-
ity (PWV) measures performed at the carotid-femoral (cfPWV), brachial-
ankle (baPWV), and femoral-ankle (faPWV) segments. Fasting glucose 
≥126 mg/dl, glycated hemoglobin (HbA1c) ≥6.5%, or currently taking 
diabetes medication defined diabetes. Fasting glucose 100–125 mg/dl 
or HbA1c 5.7%–6.4% among those without diabetes defined predia-
betes. Cross-sectional associations were modeled using multivariable 
linear regression.
RESULTS
Among 4,279 eligible participants with cfPWV measures (mean age 
75 years), 22% were African–American, 25.5% had diabetes, and 54.7% 
had prediabetes. Compared to those with normal glucose, cfPWV was 
95.8 cm/s higher (stiffer) on average for those with diabetes (for refer-
ence: being 1 year older was associated with 14.4 cm/s higher cfPWV). 
Similar findings were seen for diabetes and baPWV, although attenu-
ated. Interestingly, faPWV was 17.6 cm/s lower for those with diabetes 
compared to normal glucose. There was a significant positive associa-
tion between baPWV and prediabetes. Among those with diabetes, 
cfPWV was higher for those with albuminuria, reduced kidney function, 
duration of diabetes ≥10 years, and elevated HbA1c (HbA1c ≥7).
CONCLUSION
Among older adults, diabetes is associated with higher central arte-
rial stiffness and lower peripheral arterial stiffness, and prediabetes is 
associated with higher baPWV. Cross-sectionally, the magnitude of the 
effect of diabetes on central stiffness is equivalent to 6 years of arterial 
aging.
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impaired glucose tolerance to newly diagnosed diabetes 
in comparison to those with normal glucose, although no 
association was seen for prediabetes.12 Further understand-
ing of the association of prediabetes with arterial stiffness is 
needed.
Prior studies of the association of prediabetes and diabe-
tes with PWV have been primarily performed in selected 
clinical populations, Asian populations, and subsets from 
community cohorts, with results shown only for single PWV 
segments.13–15 No prior studies have measured PWV in a 
population-based US cohort of older adults with detailed 
measures of diabetes. We set out to study central (cfPWV), 
peripheral (femoral-ankle PWV (faPWV)), and composite 
central and peripheral (baPWV) measures of arterial stiff-
ness and their cross-sectional association with diabetes and 
prediabetes in a population-based bi-ethnic cohort of older 
adults (mean age 75 years) from the Atherosclerosis Risk in 
Communities (ARIC) study.
METHODS
The ARIC study is an ongoing community-based obser-
vational cohort study of cardiovascular disease and its risk 
factors. The original cohort of 15,792 was recruited in 1987–
1989 from the following 4 US communities: Forsyth County, 
North Carolina (both African–Americans and Whites); 8 
suburbs of Minneapolis, Minnesota; Washington County, 
Maryland; and Jackson, Mississippi (African–Americans 
only).16 We conducted a cross-sectional analysis of data col-
lected at the 5th study visit (2011–2013) when the age range 
was 66–90  years. There were 10,036 participants alive and 
eligible for the 5th study visit, of which 6,538 participated in 
the study visit (65% response rate for eligible participants), 
and 5,918 completed the full exam in the clinic, of which 
5,683 had PWV measurements. After the exclusions (see 
Supplementary Material for details) , a total of 4,682 (82%) 
participants remained. Depending on the PWV measure-
ment analyzed, the final analytic sample excluded those with 
missing and outlying values, as defined by values greater 
than 3 SDs above the mean. The ARIC study was approved 
by Institutional Review Boards (IRBs) at all centers, and all 
procedures were in accordance with the ethical standards of 
these IRBs. Participants provided informed consent.
Participants were asked to bring in all of their medica-
tions, fast for 8 hours, and avoid tobacco, caffeinated bev-
erages, and vigorous physical activity the day of the study 
visit. All measures were performed by trained staff and using 
standardized methodology (protocols are available at https://
www2.cscc.unc.edu/aric/cohort-manuals).
PWV was measured using the VP-1000 Plus system 
(Omron, Kyoto, Japan). With the participant supine, the fol-
lowing were applied: blood pressure cuffs on the arm and 
ankle, a phonocardiogram sensor, left carotid and femo-
ral arterial sensors, and electrocardiography clips on both 
wrists. After 5–10 minutes of rest, a minimum of 2 meas-
ures were performed, and the last 2 nonzero measures were 
averaged. Carotid and femoral arterial pressure waveforms 
were acquired for 30 seconds by applanation tonometry 
sensors, and a segmometer (Rosscraft, Surray, Canada) was 
used to measure the carotid femoral distance. The carotid 
femoral path length (cm) was calculated as the distance from 
the carotid to femoral arteries minus the distance from the 
suprasternal notch to carotid artery. Bilateral brachial and 
posterior-tibial arterial pressure waveforms were detected 
over 10 seconds by extremity cuffs connected to plethysmo-
graphic and oscillometric pressure sensors. Using height-
based formulas, distances for baPWV and faPWV were 
automatically calculated.17 In this analysis, right-sided meas-
ures were used for baPWV and faPWV. See Supplementary 
Material for details regarding the quality assurance protocol 
for PWV measures.
Behavioral and lifestyle factors were assessed with inter-
viewer-administered questionnaires. Participant’s brought 
in medications, and names and dosages were documented 
and classified. A standard resting 12-lead electrocardiogram 
was read at the Epidemiological Cardiology Research Center 
located at Wake Forest University School of Medicine, and 
abnormalities were coded with Minnesota codes.18 Body 
weight and height were measured in scrub suits. Seated blood 
pressure was measured 3 times, and the average of the last 2 
measures was used. Hypertension was defined as blood pres-
sure ≥140 mm Hg systolic, or ≥90 mm Hg diastolic, or tak-
ing antihypertensive medication. Albuminuria was defined 
as albumin-to-creatinine ratio > 30 mg/g from a urine test, 
and includes those with macroalbuminuria. A  standard 
venipuncture protocol was followed to obtain blood sam-
ples, processed within 90 minutes, and shipped weekly to 
the Atherosclerosis Clinical Research Laboratory (ACRL) at 
the Baylor College of Medicine and the Advanced Research 
and Diagnostic Laboratory (ARDL) at the University of 
Minnesota (see Supplementary Material for details).
Diabetes mellitus was defined as fasting glucose ≥126 mg/
dl, or glycated hemoglobin (HbA1c) ≥6.5%, or currently 
taking diabetes medication including insulin or oral hypo-
glycemic agents. Prediabetes was defined among those with-
out diabetes, as fasting glucose of 100–125 mg/dl or HbA1c 
5.7%–6.4%. Normal glucose was defined as fasting glucose 
<100 mg/dl and HbA1c <5.7% among those without diabe-
tes. Duration of diabetes of 10 or more years was based on 
self-report, fasting glucose, and use of diabetes medications 
from the 5 study visits and from the annual phone calls.
Statistical analysis
The associations between diabetes status and continuous 
PWV measures were examined using multivariable linear 
regression analysis adjusting for race-center, age, gender, 
heart rate, hypertension, current smoking status, and body 
mass index. Models included those with nonmissing values 
for all covariates. From these models, the cross-sectional 
effect of age on PWV was estimated (among nonsmokers 
without diabetes) as a measure of the effect of aging on PWV. 
Effect modification by gender or race was tested by including 
interaction terms in the model along with the main effects 
(P  <  0.1 threshold for significance of interaction). Results 
were presented stratified for significant interactions. Among 
those with diabetes, cross-sectional associations with PWV 
were stratified into to those with and without the following: 
(i) albuminuria, (ii) reduced kidney function as defined by 
glomerular filtration rate <60 ml/min/1.73 m2, (iii) elevated 
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HbA1c as defined by HbA1c ≥7%, and (iv) greater than or 
equal to 10 years duration of diabetes.
RESULTS
There were 1,090 participants with diabetes, 2,340 
with prediabetes, and 849 without diabetes and with nor-
mal glucose (Table  1 shows numbers for cfPWV meas-
ures only, as numbers vary by PWV measure). Mean 
age was 75 (range of 66–90  years), with 22% African–
Americans and 60% women. The mean age across dia-
betes status was similar. There were a higher percentage 
of women (69%) among those with normal glucose com-
pared to those with diabetes (53%). Hypertension was 
more prevalent in those with diabetes at 84%, compared 
to 70% of those with prediabetes, and 61% among those 
with normal glucose. Albuminuria, defined as albumin-
to-creatinine ratio >30 mg/g, was more prevalent among 
those with diabetes (22%) compared to those without 
diabetes (10%).
Multivariable-adjusted cfPWV (aortic PWV) and baPWV 
were higher on average for those with diabetes compared 
with those free of diabetes or prediabetes (Table 2, 95.8 cm/s 
for cfPWV and 51.6 cm/s for baPWV). For comparison, the 
average difference in cfPWV by year of age among non-
smokers without diabetes is 14.4 cm/s. Peripheral PWV 
measured by faPWV was negatively associated with diabetes 
compared with those with normal glucose (−17.6 cm/s for 
faPWV). There was a significant association of prediabetes 
with baPWV (difference = 23.4 cm/s, 95% CI: 1.1–45.7), but 
there was no statistically significant association with cfPWV 
or faPWV.
Race and gender were evaluated as effect modifiers of the 
association of diabetes and prediabetes with PWV. There was 
no significant effect modification by gender (P values range 
from 0.17–0.97, results not shown). There was effect modifi-
cation of diabetes by race for cfPWV only (P = 0.06; Table 3). 
The association of diabetes and cfPWV was stronger among 
White participants compared to African-American par-
ticipants. cfPWV was 69.3 cm/s higher, on average, for 
Table 1. Characteristics of participants (N = 4,279) with cfPWV at ARIC visit 5 (2011–2013)a, stratified by diabetes status 
Normal glucose 
(n = 849)
Prediabetes 
(n = 2,340)
Diabetes mellitus  
(n = 1,090)
Age (years), mean (SE) 75.2 (0.2) 75.3 (0.1) 75.0 (0.1)
BMI (kg/m2), mean (SE) 26 (0.1) 27.7 (0.1) 29.6 (0.1)
Women, n (%) 590 (69) 1,385 (59) 574 (53)
African–American, n (%) 144 (17) 443 (19) 344 (32)
ARIC study center, n (%)
 Jackson, MS 140 (16) 409 (17) 324 (30)
 Forsyth, NC 160 (19) 525 (22) 191 (18)
 Washington County, MD 234 (28) 620 (26) 318 (29)
 Minneapolis, MN 315 (37) 786 (34) 257 (24)
Current smoker, n (%) 52 (6) 138 (6) 56 (5)
Hypertensionb, n (%) 518 (61) 1,640 (70) 916 (84)
Prevalent CHDc, n (%) 70 (8) 287 (12) 189 (18)
Heart rate (beats/min), mean (SE) 63.3 (0.3) 64.1 (0.2) 66.5 (0.3)
Fasting glucose (mg/dl), mean (SE) 92.7 (0.2) 106.1 (0.2) 139.5 (1.2)
Hemoglobin A1c (%), mean (SE) 5.3 (0.01) 5.7 (0.01) 6.7 (0.03)
Cholesterol-lowering medication, n (%) 338 (40) 1,245 (54) 770 (71)
Antihypertensive medication, n (%) 491 (58) 1,620 (69) 966 (89)
eGFR < 60 ml/min/1.73m2, n (%) 191 (22) 584 (25) 326 (30)
Albumin-to-creatinine ratio >30 mg/g, n (%) 71 (10) 223 (11) 221 (22)
cfPWV (cm/s), mean (SE) 1,107 (10) 1,140 (6) 1,239 (10)
baPWV (cm/s), mean (SE) 1,710 (11) 1,733 (7) 1,750 (10)
faPWV (cm/s), mean (SE) 1,112 (6) 1,101 (4) 1,075 (6)
Abreviations: ARIC, Atherosclerosis Risk in Communities; baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; cfPWV, 
carotid-femoral pulse wave velocity; CHD, coronary heart disease; eGFR, glomerular filtration rate; faPWV, femoral-ankle pulse wave velocity.
aThere were differing numbers with PWV measures by segment. This table shows the numbers for those with cfPWV.
bHypertension was defined as blood pressure ≥140 mm Hg systolic, or ≥90 mm Hg diastolic, or taking antihypertensive medication.
cPrevalent CHD was defined as a history of myocardial infarction, coronary revascularization procedure, coronary artery bypass surgery, or 
the development of any of these during the years of the study prior to visit 5.
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African–Americans with diabetes compared to those with 
normal glucose and free of diabetes, whereas among White 
participants, cfPWV was 106 cm/s higher among those with 
diabetes compared to those with normal glucose and free of 
diabetes. There was no significant effect modification by race 
of the association between prediabetes and cfPWV.
Albuminuria, duration of diabetes ≥10 years, and elevated 
HbA1c were associated with higher cfPWV among those 
with diabetes (Table 4). Among those with diabetes, the pres-
ence of albuminuria as compared to absence of albuminuria 
was strongly associated with higher cfPWV and baPWV, 
with a difference of 114.4 cm/s for cfPWV and 58.6 cm/s for 
baPWV. A similar association was observed for reduced kid-
ney function as estimated by reduced glomerular filtration 
rate and cfPWV, although not significant. Among those with 
diabetes, presence of reduced kidney function compared to 
normal kidney function was not significantly different for 
cfPWV but was associated with significantly lower baPWV 
and faPWV. Duration of diabetes ≥10 years was also associ-
ated with a higher cfPWV (84.2 cm/s, 95% CI: 48, 120.3) and 
a lower faPWV (−34.3 cm/s, 95% CI: −55.5, −13.1). Duration 
of diabetes ≥10 years was not statistically significantly asso-
ciated with baPWV.
DISCUSSION
In this large cohort of older adults, we found that diabe-
tes mellitus is associated with aortic stiffness measured by 
cfPWV. We estimate the magnitude of this association to 
be comparable to over 6  years of chronologic age among 
nonsmokers without diabetes, on average. Interestingly, the 
association of diabetes with peripheral stiffness measured 
by faPWV was in the opposite direction from that of aortic 
stiffness measured by cfPWV such that diabetes was associ-
ated with lower peripheral stiffness. There was an interac-
tion by race that indicated a stronger association between 
diabetes and cfPWV among Whites. Prediabetes was only 
associated with higher baPWV, a composite of central and 
peripheral arterial stiffness.
Several smaller studies reported on the association of dia-
betes with aortic stiffness as measured by cfPWV.15,19–23 In 
our study of elderly adults, we found a significant associa-
tion between aortic stiffness and diabetes, but did not with 
prediabetes. We add to the literature that the association of 
diabetes with aortic stiffness (cfPWV) did not vary by gen-
der but was significantly stronger in Whites compared to 
African–Americans.
We did not find an association of prediabetes with cfPWV 
or faPWV, but we did find an association with baPWV in 
older adults. This was similarly found in a healthy Chinese 
population.12 Studies in younger populations have shown an 
association with aortic stiffness and insulin resistance (and/
or hyperglycemia) among those without known diabetes.24,25
Diabetes was associated with lower peripheral arterial 
stiffness, opposite from the associations seen for cfPWV and 
baPWV. This was unexpected, and to our knowledge has 
not been shown previously. We hypothesize that the arterial 
wall tissue remodeling that occurs with diabetes may differ 
pathophysiologically in muscular versus elastic large arter-
ies, and that loss of elasticity and recoil does not necessarily Ta
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translate into stiffening of the muscular arteries. Tsuchikura 
et al. found opposing directions of effect for the association 
of peripheral and central stiffness with coronary artery dis-
ease,26 including in a subset of participants with type 2 dia-
betes. Similarly, a recent publication from the ARIC study 
reported that cfPWV and baPWV were positively associated 
with age and with HbA1c, whereas faPWV was not.27 These 
studies support the observation that peripheral stiffness 
does not have the same associations with coronary heart dis-
ease, or its risk factors, that are observed for central arterial 
stiffness.
baPWV is being used in the clinical setting primarily in 
East Asian countries, presumably because its cuff-based 
measurement is considerably easier to implement compared 
to cfPWV or faPWV, which require tonometry of the carotid 
and femoral arteries.28 baPWV is not widely used elsewhere, 
however, possibly due to uncertainty of interpretation of this 
composite measure since it spans from the central elastic 
arteries to the peripheral arteries with a high smooth muscle 
component.5,29
In our study, the association between baPWV (i.e., 
51.6 cm/s difference in baPWV for diabetes) and diabetes 
was intermediate between that seen for cfPWV (95.8 cm/s 
difference in cfPWV for diabetes) and faPWV (−17.6 cm/s 
difference in faPWV for diabetes). Our findings here sup-
port those from smaller studies in Asian populations that 
have also found that baPWV was associated with diabetes 
and prediabetes.14,30,31
Among participants with diabetes, we found that albu-
minuria, 10  years or greater duration of diabetes, and ele-
vated HbA1c were associated with higher aortic stiffness. 
The Edinburgh Type 2 Diabetes Study (mean age 69)  also 
observed that duration of diabetes and HbA1c was associated 
with higher cfPWV.32 In addition, we observed that albumi-
nuria was associated with baPWV but not with faPWV. In a 
small study of those with type 2 diabetes (N = 134), albumi-
nuria and 10 years duration of diabetes were associated with 
large artery stiffness (aortic PWV).33
The mechanisms behind the associations of arterial 
stiffness with aging and diabetes are likely similar, reflect-
ing adverse effects on the arterial wall and kidney related 
to the development of advanced glycation end products.34 
Although diabetes likely accelerates arterial stiffening 
through multiple pathways, the accelerated production of 
advanced glycation end products that cross-link with col-
lagen and elastin resulting in diabetes-associated vascular 
end-organ damage has been postulated to play a role.1,34 The 
Rotterdam study had similar findings, although not signifi-
cant for reduced kidney function.35
This is the largest study to have measured PWV in a popu-
lation-based US cohort of older adults with detailed measures 
of diabetes. Importantly, PWV was measured in central and 
peripheral artery segments. There are several limitations to 
consider. The associations described here are cross-sectional; 
therefore, temporality of associations cannot be inferred. 
A glucose load test was not performed, suggesting that some 
impairments could have been misclassified as normal. Due 
to occasional equipment malfunction not all participants had 
PWV measured. Lastly, aortic length was estimated over the 
body, which does not reflect aortic tortuosity.
In conclusion, this report contributes to the literature on 
arterial stiffness and diabetes with segment-specific PWV 
measures in a large, older population inclusive of African-
American men and women. We estimate that the magnitude 
of the cross-sectional effect of diabetes on aortic stiffness is 
equivalent to 6 years of aging. Among those with diabetes, we 
find that duration of diabetes, reduced kidney function, and 
albuminuria, a known manifestation of diabetic nephropa-
thy, strengthen the observed association with aortic stiffness. 
Our results document heterogeneity of associations between 
arterial territories such that differences in aortic stiffness 
measured by cfPWV are greater among those with diabetes. 
These results are consistent with greater age-related aortic 
tissue remodeling among persons with diabetes, seemingly 
related to duration of diabetes and an indicator of end-organ 
damage. Considering the adverse hemodynamic conse-
quences of central artery stiffness, not only replication of 
these results, but also evaluation of the central pressure and 
flow pulsatility characteristics among persons with diabetes 
are called for. 
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